 Cumberland Pharmaceuticals Inc. NASDAQ: CPIX a specialty pharmaceutical company, today announced an initiative to increase availability of Vaprisol conivaptan hydrochloride injection for treating hyponatremia, associated with critical care patients during the COVID-19 pandemic. Vaprisol is an FDA approved treatment for hyponatremia, a potentially life-threatening condition that can often afflict patients in the Intensive Care Unit ICU. 